Evidence map›Paper›PMID 38861891›Full record

ArticleClinical nutrition (Edinburgh, Scotland)2024

Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.

Clinton T Elfers, Kylie S Chichura, Emily F Ashlaw, Oleg G Chepurny, George G Holz, Robert P Doyle, Christian L Roth

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical nutrition (Edinburgh, Scotland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Clinton T ElfersSeattle Children's Research Institute, 1900 Ninth Ave, Seattle WA 98101, USA.
Kylie S ChichuraSyracuse University, Department of Chemistry, 111 College Place, Syracuse, NY 13244, USA; Alltrna, Cambridge, MA, USA.
Emily F AshlawSyracuse University, Department of Chemistry, 111 College Place, Syracuse, NY 13244, USA.
Oleg G ChepurnyState University of New York, Upstate Medical University, Department of Medicine, Syracuse, NY 13210, USA.
George G HolzState University of New York, Upstate Medical University, Department of Medicine, Syracuse, NY 13210, USA.
Robert P DoyleSyracuse University, Department of Chemistry, 111 College Place, Syracuse, NY 13244, USA; State University of New York, Upstate Medical University, Department of Medicine, Syracuse, NY 13210, USA. Electronic address: Rpdoyle@syr.edu.
Christian L RothSeattle Children's Research Institute, 1900 Ninth Ave, Seattle WA 98101, USA; Seattle Children's Hospital, University of Washington, Department of Pediatrics, Seattle, WA 98105, USA. Electronic address: Christian.roth@seattlechildrens.org.

Funding

PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON · 1986 to 2026
$30.4M
Development of Anorexigenic and Glucoregulatory Chimeric PeptidesR01DK135125 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Robert P Doyle, Christian Ludwig Roth · 2023 to 2026
$2.7M
Alpha7 Nicotinic Acetylcholine Receptor Regulation of Glucagon-Like Peptide-1 Incretin Hormone Action.R01DK122332 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI HOLZ, GEORGE G · 2020 to 2023
$1.6M
NIDDK NIH HHS P30 DK035816NIDDK NIH HHS R01 DK122332NIDDK NIH HHS R01 DK135125
6 · The paper itself

Abstract

introductionWhile therapies based on endogenous gut peptides such as glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been compelling therapeutic agents for obesity and type 2 diabetes (T2D), only a few have achieved long-term weight loss and all have shown significant side-effects, including nausea/malaise and gastrointestinal ailments.

objectiveAs the pathophysiology of obesity is driven by dysregulation of multiple, inter-related, pathways, we tested a novel peptide targeting multiple receptors of complementary neurocircuits regulating the controls of energy balance.

methodsResponse to daily injections of GEP44, a GLP-1R and neuropeptide Y1R and Y2R receptor (Y1R/Y2R) triple agonist was tested vs. the GLP-1R agonist liraglutide (LIRA) in diet-induced obese (DIO) male and female rats. Glucose tolerance tests after intraperitoneal injection of glucose (IPGTT) were performed at baseline and after 14-d of treatment in GEP44 treated rats. Other metabolic parameters were assessed in blood at the end of a 28-d intervention.

resultsUpon conclusion at 28-d, body weight reduction compared to vehicle was -15.6%/-11.9% in response to GEP44, vs. -9.7%/-5.1% after LIRA, males, and females, respectively. Significant reductions of cumulative food intake occurred over 28-d in female rats treated with GEP44 (-30%; p < 0.0001), vs. LIRA (-10%), and in male rats GEP44 (-39%; p < 0.0001), vs. LIRA (-20%; p = 0.003). In IPGTTs, a similar stimulation glucose induced insulin secretion was noted in rats treated with GEP44 and LIRA.

conclusionThe strong reductions of body weight in response to long-term applications of the triple agonist GEP44 confirms the therapeutic potential of targeting multiple receptors for achieving more robust and potentially more sustained improvement of energy balance.

Indexed as

EatingGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideObesityAnimalsBlood GlucoseBody WeightDiet, High-FatFemaleGlucose Tolerance TestInsulinMaleRatsRats, Sprague-DawleyReceptors, Neuropeptide YWeight LossBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsInsulinLiraglutideneuropeptide Y2 receptorReceptors, Neuropeptide YBody weightCalorie intakeDrug interventionGlucose toleranceMonomeric multi-receptor agonistObesity

Identifiers

PMID38861891
PMCPMC12285839

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.